Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Allon Therapeutics Inc NPCUF

Allon Therapeutics, Inc. is a Canada-based Company, which develops treatments for neurodegenerative diseases. The Company is engaged in pre-clinical and clinical development of proprietary neuroprotective compounds which may be applied for the potential treatment of Alzheimer's Disease, Parkinson's Disease, senile dementia, glaucoma, traumatic head injury, neuronal damage due to stroke and other conditions involving neurodegeneration. The Company's drug, davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA).


GREY:NPCUF - Post by User

Post by modulexon Nov 15, 2017 6:36pm
243 Views
Post# 26972132

N.A.P.E.C. : A MYSTERIOUS STOCK

N.A.P.E.C. : A MYSTERIOUS STOCKwhen reading about napec, it is an open secret that there are takeover talks going on behind the scene. the share price drifted to $1.31 today but closed up a penny higher than yesterday, to close at $1.34. it has traded in that pattern since the hefty buyings by Desjardins Securities which started in september 2017 at $1.20 up to $1.35. the 52-weeks high is $1.36 the stock cannot be lifted at this slow pace for ever. i expect to wake up one morning and learn of a sale. napec is afterall operating largely in the United States. So, an american competitor will take it on without any doubt.
<< Previous
Bullboard Posts
Next >>